We found that 24 h after two rounds of antibody administration (Figure 2E), the combination of anti-BTLA and anti-PD-L1 mAbs significantly increased the tumor infiltration of CD8+ and CD4+ T cells compared to that in the other groups (Figure 2F). Here, CD4 is linked to neoplasm.